[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO2024257023A1 - Ligands de pseudokinase tyk2 et leurs utilisations - Google Patents

Ligands de pseudokinase tyk2 et leurs utilisations Download PDF

Info

Publication number
WO2024257023A1
WO2024257023A1 PCT/IB2024/055815 IB2024055815W WO2024257023A1 WO 2024257023 A1 WO2024257023 A1 WO 2024257023A1 IB 2024055815 W IB2024055815 W IB 2024055815W WO 2024257023 A1 WO2024257023 A1 WO 2024257023A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
compound according
compound
cycloalkyl
heteroaryl
Prior art date
Application number
PCT/IB2024/055815
Other languages
English (en)
Other versions
WO2024257023A8 (fr
Inventor
Suresh KURHADE
Garima PRIYADARSHANI
Shailendra SISODIYA
Mahesh HALLE
Jeevak Sopanrao KAPURE
Jissy Akkarapattiakal KURIAPPAN
Sanchari Basu MALLIK
Amol TANDON
Ganesan Subramaniam
Abishek Venkatasubramanian IYER
Original Assignee
Alembic Pharmaceuticals Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alembic Pharmaceuticals Limited filed Critical Alembic Pharmaceuticals Limited
Publication of WO2024257023A1 publication Critical patent/WO2024257023A1/fr
Publication of WO2024257023A8 publication Critical patent/WO2024257023A8/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des composés de formule A qui sont utiles dans la modulation de l'inflammation et le traitement de troubles associés par action sur TYK2 pour provoquer une inhibition de la transduction de signal médiée par TYK2. Dans certains modes de réalisation, le trouble médié par TYK2 est un trouble auto-immun, un trouble inflammatoire, un trouble endocrinien, un trouble neurologique, un trouble prolifératif ou un trouble associé à une transplantation.
PCT/IB2024/055815 2023-06-14 2024-06-14 Ligands de pseudokinase tyk2 et leurs utilisations WO2024257023A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN202321040658 2023-06-14
IN202321040658 2023-06-14

Publications (2)

Publication Number Publication Date
WO2024257023A1 true WO2024257023A1 (fr) 2024-12-19
WO2024257023A8 WO2024257023A8 (fr) 2025-01-16

Family

ID=91699945

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2024/055815 WO2024257023A1 (fr) 2023-06-14 2024-06-14 Ligands de pseudokinase tyk2 et leurs utilisations

Country Status (1)

Country Link
WO (1) WO2024257023A1 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014074661A1 (fr) 2012-11-08 2014-05-15 Bristol-Myers Squibb Company Composés hétérocycliques substitués par amide, utiles comme modulateurs d'il-12, il-23 et/ou de réponses à l'ifnα
WO2014074670A1 (fr) 2012-11-08 2014-05-15 Bristol-Myers Squibb Company Composés de pyrimidine substitués par alkylamide utiles dans la modulation d'il-12, il-23 et/ou ifnα
WO2020086616A1 (fr) * 2018-10-22 2020-04-30 Fronthera U.S. Pharmaceuticals Llc Inhibiteurs de tyk2 et leurs utilisations
WO2022105771A1 (fr) * 2020-11-17 2022-05-27 江苏恒瑞医药股份有限公司 Dérivé hétérocyclique azoté, son procédé de préparation et son application médicale
CN116262739A (zh) * 2021-12-13 2023-06-16 上海翰森生物医药科技有限公司 含氮芳基衍生物调节剂、其制备方法和应用

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014074661A1 (fr) 2012-11-08 2014-05-15 Bristol-Myers Squibb Company Composés hétérocycliques substitués par amide, utiles comme modulateurs d'il-12, il-23 et/ou de réponses à l'ifnα
WO2014074670A1 (fr) 2012-11-08 2014-05-15 Bristol-Myers Squibb Company Composés de pyrimidine substitués par alkylamide utiles dans la modulation d'il-12, il-23 et/ou ifnα
WO2020086616A1 (fr) * 2018-10-22 2020-04-30 Fronthera U.S. Pharmaceuticals Llc Inhibiteurs de tyk2 et leurs utilisations
WO2022105771A1 (fr) * 2020-11-17 2022-05-27 江苏恒瑞医药股份有限公司 Dérivé hétérocyclique azoté, son procédé de préparation et son application médicale
CN116262739A (zh) * 2021-12-13 2023-06-16 上海翰森生物医药科技有限公司 含氮芳基衍生物调节剂、其制备方法和应用

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
"Chemistry of Functional Groups", JOHN WILEY & SONS
"Organic Reactions", 1942, JOHN WILEY & SONS
FUHRHOP, J.PENZLIN G: "Organic Synthesis: Concepts, Methods, Starting Materials", 1994, JOHN WILEY & SONS
H. O. HOUSE: "Modern Synthetic Reactions", 1972, W. A. BENJAMIN, INC
HOFFMAN, R.V.: "Organic Chemistry, An Intermediate Text", 1996, OXFORD UNIVERSITY PRESS
LAROCK, R. C: "Industrial Organic Chemicals: Starting Materials and Intermediates: An Ullmann's Encyclopedia", 1999, JOHN WILEY & SONS
S. R. SANDLER ET AL.: "Organic Functional Group Preparations", 1983, JOHN WILEY & SONS, INC.
SOLOMONS, T. W. G: "Modern Carbonyl Chemistry", 2000, JOHN WILEY & SONS
STOWELL, J.C: "Intermediate Organic Chemistry", 1993, WILEY-INTERSCIENCE
T. L. GILCHRIST: "Advanced Organic Chemistry: Reactions, Mechanisms, and Structure", 1992, WILEY-INTERSCIENCE

Also Published As

Publication number Publication date
WO2024257023A8 (fr) 2025-01-16

Similar Documents

Publication Publication Date Title
EP3870579B1 (fr) Inhibiteurs de tyk2 et leurs utilisations
AU704133B2 (en) Pharmaceutically active quinazoline compounds
US9745297B2 (en) Compounds as modulators of RORC
KR101605576B1 (ko) 페녹시피리디닐아미드 유도체 및 ｐｄｅ４ 매개 질환 상태의 치료에서의 그의 용도
CA2693904A1 (fr) Composes heterocycliques utiles comme inhibiteurs de mk2
US20120309739A1 (en) Akt / pkb inhibitors
BR112016028273B1 (pt) Composto de fórmula i-a, forma sólida de um composto de fórmula i-1 e seu processo de preparação
CA2716410A1 (fr) Derives 1-heterocyclyl-1,5-dihydro-pyrazolo[3,4-d]pyrimidin-4-one et leur utilisation en tant qu'inhibiteurs de pde9a
CN113365631B (zh) 布鲁顿酪氨酸激酶抑制剂
EP1463730A1 (fr) Derives de pyrazoloparidazine
AU2021373162B2 (en) Pyrazolopyridazinone compound, and pharmaceutical composition and use thereof
KR20230069984A (ko) Tyk2 억제제 및 그의 용도
JP2022540671A (ja) サイクリン依存性キナーゼの阻害剤
AU2020386189B2 (en) Adenosine receptor antagonist compounds
CN112778336B (zh) 一类含氮稠环类sting调节剂类化合物、制备方法和用途
CN114524810B (zh) 一类嘧啶并杂环类化合物、制备方法和用途
US12110299B2 (en) Thiazole derivatives and pharmaceutically acceptable salts thereof
WO2024257023A1 (fr) Ligands de pseudokinase tyk2 et leurs utilisations
CN112088003B (zh) 制备嘧啶基-4-氨基吡唑化合物的工艺
WO2024127363A1 (fr) Ligands de pseudokinase tyk2 et leurs utilisations
Colotta et al. Synthesis of 4-amino-6-(hetero) arylalkylamino-1, 2, 4-triazolo [4, 3-a] quinoxalin-1-one derivatives as potent A2A adenosine receptor antagonists
AU2010205630A1 (en) 6-phenyl-LH-imidazo [4, 5-c] pyridine-4-carbonitrile derivatives as cathepsin S and/or cathepsin K inhibitors
WO2024255795A1 (fr) Inhibiteurs de kras et leurs utilisations
WO2024041555A1 (fr) Procédés de fabrication d'inhibiteurs de kinase
CA2716202A1 (fr) Derives de pyrrolo[2,3-d]pyrimidin-2-ylamine comme inhibiteurs de pkc-theta